RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MIAMI, Nov. 30, 2016 -- OPKO Health, Inc. (NASDAQ:OPK), announces that its senior management team will host one-on-one investor meetings with institutional investors participating at the following investor conferences in December:
- Evercore ISI MedTools Investor Conference taking place November 30-December 1, 2016 at the Boston Harbor Hotel;
- Citi 2016 Global Healthcare Conference taking place December 7-8, 2016 at the Lott New York Palace in New York City;
- Guggenheim Securities 4th Annual Boston Healthcare Conference taking place on December 13, 2016 at The InterContinental Boston.
Attendance at these conferences is by invitation only. The investor presentation used at the conferences will be posted to the Investor Relations page of the Company's website at www.opko.com under “Events” on the day of the event.
Institutional investors attending these conferences who are interested in meeting with OPKO Health management should contact their representatives at Evercore ISI, Citi and/or Guggenheim Securities, respectively.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation PDUFA date: January 2017), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.
Company OPKO Health, Inc. Tara Mackay, 305-575-4100 Investor Relations or Media Rooney & Associates Terry Rooney, 212-223-0689 [email protected] or Marion Janic, 212-223-4017 [email protected] or Investors LHA Anne Marie Fields, 212-838-3777 [email protected] or Bruce Voss, 310-691-7100 [email protected]
